E3 ligase ligand-linker conjugates 49 are primarily utilized in the field of targeted protein degradation, particularly in the development of PROTACs (Proteolysis Targeting Chimeras). These conjugates play a crucial role in designing molecules that can selectively degrade disease-causing proteins by recruiting E3 ubiquitin ligases to the target protein. This process leads to ubiquitination and subsequent degradation by the proteasome, offering a promising therapeutic strategy for conditions such as cancer, neurodegenerative diseases, and other disorders driven by aberrant protein expression. The linker component ensures proper spatial orientation and binding efficiency between the E3 ligase and the target protein, enhancing the specificity and effectiveness of the degradation process. This approach is gaining traction in drug discovery due to its ability to target proteins traditionally considered "undruggable" by conventional small-molecule inhibitors.